Pharmacovigilance among patients with multi drug resistance tuberculosis (MDR-TB) treatment-a prospective study

Ashalatha D; Roopkumar C; Premraj K; Vani V; Narayana swamy P; Venkatesh P

doi:10.37022/jiaps.v7i1.308

D.Ashalatha Pharm d final year student, Jagan’s Institute of Pharmaceutical Sciences, Nellore
C.Roopkumar Pharm d final year student, Jagan’s Institute of Pharmaceutical Sciences, Nellore
K.Premraj Pharm d final year student, Jagan’s Institute of Pharmaceutical Sciences, Nellore
V.Vani Pharm d final year student, Jagan’s Institute of Pharmaceutical Sciences, Nellore
P.Narayana swamy Associate Professor, Dept.of Pharmacy practice, Jagan’s Institute of Pharmaceutical Science, Nellore
P. Venkatesh Principal Jagan’s Institute of Pharmaceutical Science, Nellore

DOI https://doi.org/10.37022/jiaps.v7i1.308

Abstract

Background: ADRs are frequent in patients of MDR-TB on DOTs-Plus drug regimen. Current study was carried out in tertiary care hospital. Recognition of types and frequency of adverse drug reactions in Intensive and continuation phase of MDR- TB Patients.

Methods: It was a prospective observational study conducted in Damien Foundation Urban Leprosy & TB Centre, Nellore. All the MDR-TB patients admitted at the directly observed treatment, short course plus (DOTS plus) Center were enrolled and were monitored for ADRs. The causality and severity of the reactions were determined using Naranjo algorithm.

Results: A total of 200 tuberculosis patients of MDR-TB on DOTS therapy were enrolled for the study. Out of 200 patients, 10 were dropouts, 10 defaulted so 190 patients assessed for ADRs, 129 patients developed 109 (56.48%) adverse drug reactions. The higher numbers of ADRs were observed in age group 31- 40yrs followed by 21-30yrs which were more common in men. Majority of adverse drug reactions were Gastrointestinal (GI) problems 48 (37.20%), followed by Ototoxicity 7 (5.42%) and Psychiatric Manifestations 3 (2.321 %) and skin problems 3 (2.32%). On evaluation of the causality of ADRs, majority were found to be Possible (57.95%). The severity assessment showed that most of the patients ADRs were of moderate level (42.04%).

Conclusions: ADRs are major factor limiting completion of drug therapy under RNTCP and occurrence of drug resistance which requires attention of all health care professionals.

Keywords: ADRs, Causality and severity, DOTS therapy, Drug resistance, MDR-TB

Downloads

Download data is not yet available.

References

1. Directorate General of Health Services, Ministry of Health and Family Welfare, Government of India; New Delhi. Central TB Division. Guidelines on Programmatic Management of Drug Resistant TB (PMDT) in India. New Delhi: May 2012.
2. WHO. Global Tuberculosis Report 2016. [Internet]. 2016. Available at: rchandq=intitle:No+Title#0http://scholar.google.com/scholar?hl=enandbtnG=Sea
3. National and state statistics TB statistics for India. Organisation WH, Control GT. MDRTB Statistics for India. 2015:1-9.
4. Joseph P, Desai VB, Mohan NS, Fredrick JS, Ramachandran R, Raman B, et al. Outcome of standardized treatment for patients with MDR-TB from Tamil Nadu, India. The Ind J of Med Resea. 2011 May;133(5):529.
5. Prasad R. Management of multi-drug resistant tuberculosis Practitioner’s view point. Indian Journal of Tuberculosis. 2007;54:3-11.
6. Arora VK, Sarin R, Singla R, Khalid UK, Mathuria K, Singla N, et al. DOTS-Plus for patients with multidrug-resistant tuberculosis in India: early results after three years. Ind J of Che Disea and All Scienc. 2007;49(2):75.
7. Singla R, Sarin R, Khalid UK, Mathuria K, Singla N, Jaiswal A, et al. Seven-year DOTS-Plus pilot experience in India: Results, constraints and issues. The International Journal of Tuberculosis and Lung Disease. 2009;13:976-81.
8. Hire R, Kale AS, Dakhale GN, Gaikwad N. A prospective, observational study of adverse reactions to drug regimen for multi-drug resistant pulmonary tuberculosis in Central India. Medit J of Hem and Infec Disea. 2014;6(1).
9. Singh BD, Ghulam H, Kadri SM, Qureshi W, Kamili MA, Singh H et al. Multidrug-Resistant and extensively drug resistant tuberculosis in Kashmir, India. J Infect Dev Ctries. 2010;4(1):19-23.